(Nasdaq: MDCX) Flies Under-The-Radar Following Positive Topline Results (5 Potential Catalysts)

Where innovation meets necessity

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on behalf of Medicus Pharma Ltd. (Nasdaq: MDCX) Flies Under-The-Radar Following Positive Topline Results (5 Potential Catalysts) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* April 14th Greetings, Friend! Where innovation meets necessity, a rising biotech company is taking bold steps to change the course of dermatologic oncology. The numbers tell the story: a $10.87Bn global skin cancer treatment market in 2024 on track to surge to $19.27Bn by 2032, growing at an impressive 7.42% each year. Inside this fast-moving field, a dedicated group of specialists is shaping a therapy that could redefine care and recovery for patients everywhere. Their work is fearless, their potential far-reaching, and the medical community is watching intently. Plus, add in the fact that it has a float of fewer than 9Mn shares and analyst targets suggesting meaningful upside potential, and it’s easy to see why this Nasdaq profile could start earning major attention. Take a moment to consider Medicus Pharma Ltd. (Nasdaq: MDCX) for your radar. Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents. Complete Company Details - Medicus Pharma Ltd. (Nasdaq: MDCX) Focus: Accelerating clinical development of novel therapeutics across multiple countries and continents. Specialty: Moving innovative therapies quickly through clinical stages. About SkinJect (Medicus Pharma's Wholly Owned Subsidiary) With SkinJect, the needles are the drug. The device comprises a dissolvable microneedle array (MNA) to deliver a drug directly into the top layer of skin. The drug will kill non-melanoma skin cancer by causing an immune system reaction to combat the disease. SkinJect consists of three key components: Dissolvable microneedles that penetrate the skin, dissolve and deliver the “cargo” − the drug. A cellulose-like material that forms the microneedles and carries the cargo. It is FDA-approved for human use. A chemotherapy cargo that kills cells and also stimulates an immunological response from the patient’s lesion. Also FDA-approved for human use. SkinJect Value Proposition Innovation: Patented, non-invasive microneedle patch for direct drug delivery to skin tumors. Market: BCC is the most common cancer globally; North American market projected at $15Bn by 2030. Clinical Results: Positive safety and efficacy data in early trials, with ongoing Phase 2 showing promise. Leadership: Experienced management and board with oncology and drug development expertise. Medicus Pharma (Nasdaq: MDCX) is positioned to impact standards of care in both human and veterinary medicine, with ongoing clinical and regulatory milestones. About Recent Acquisition: Antev Ltd. Antev Ltd. (“Antev”) is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, a potentially first in market product for high-risk prostate cancer patients and patients with first acute urinary retention (AUR) episodes due to enlarged prostate. Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. Teverelix: A Next-Gen GnRH Antagonist Teverelix is being developed to compete with or improve upon current GnRH antagonists like Degarelix and Relugolix as well as agonists. What sets Teverelix apart is the potential for: Rapid onset of testosterone suppression and prostate shrinkage Avoidance of testosterone flare versus agonists A longer-acting injection schedule (possibly every 6 weeks) Potential for subcutaneous and intra-muscular delivery without daily dosing (vs. Relugolix’s daily oral use) Due to superior formulation, ISRs potentially significantly milder compared to Degarelix ~ 400 pts already included in studies to date & multiple peer reviewed publications What's Next for Teverelix? Find Sources Here: MDCX Presentation. MDCX Website. ----- 5 Potential Catalysts Could Provide (Nasdaq: MDCX) With A Breakout Spark! #1. A Low Float Scenario: With roughly 8.37Mn shares in its float, volatility potential could be heightened at the drop of a hat. #2. Two Analyst Targets Suggest MDCX May Be Undervalued. Take a look at this info found over at MarketBeat: From Tuesday's close, the D. Boral Capital and Maxim Group targets project a potential upside of over 6,000% and 4,500%, respectively. On top of those, Zacks Research provided MDCX with an "Upgrade" back in September. From current chart levels, do these targets and upgrade signal (Nasdaq: MDCX) to be undervalued? #3. New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms. Medicus Pharma Ltd. has launched a year-long, 12-part national media campaign with New to The Street, boosting its visibility across television, digital, and outdoor channels. The initiative will spotlight SkinJect™, an innovative immuno-oncology platform targeting non-melanoma skin cancers, and Teverelix®, a next-generation GnRH antagonist for prostate conditions. With over 5Mn subscribers reached digitally and 80 monthly TV placements in major markets, Medicus gains unprecedented exposure, underscoring its leadership in precision-guided therapeutic innovation. #4. Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort. Medicus Pharma Ltd. reported encouraging Phase 2 results from its SKNJCT-003 study evaluating SkinJect™, a Doxorubicin Microneedle Array for basal cell carcinoma treatment. The 200μg cohort demonstrated 73% clinical and 40% histological clearance by Day 57, validating the product’s efficacy and safety. These decision-grade findings support an upcoming FDA End-of-Phase-2 meeting and enhance partnering potential. Company CEO, Dr. Raza Bokhari, emphasized the data’s strength in driving strategic growth and advancing SkinJect toward commercialization, marking a significant milestone in Medicus’ oncology pipeline. #5. A Potential Healthy Reversal Could Be Approaching For MDCX. Technical analysis reveals MDCX has several oversold indicators, suggesting a possible reversal setup may be developing. At 2:00PM EST on Monday, MDCX had a 9 and 14-Day Relative Strength Index both below 36% and a 9 and 14-Day Raw Stochastic below 15%. These technical levels suggest a profile that may be currently undervalued. ----- Coverage is kicked-off on Medicus Pharma Ltd. (Nasdaq: MDCX). Keep your eyes peeled for updates heading your way shortly. Talk soon.  All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 04/14/2026 and ending on 04/15/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifty eight thousand eight hundred USD ("Funds"). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/mdcx-7e33i/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice